Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next‐Generation Sequencing in Detecting Actionable Driver Mutations in Anti‐EGFR Naive Metastatic Colorectal Cancer

BACKGROUND: Direct comparisons between Guardant360 (G360) circulating tumor DNA (ctDNA) and FoundationOne (F1) tumor biopsy genomic profiling in metastatic colorectal cancer (mCRC) are limited. We aim to assess the concordance across overlapping genes tested in both F1 and G360 in patients with mCRC...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Gupta, Rohan, Othman, Tamer, Chen, Chen, Sandhu, Jaideep, Ouyang, Ching, Fakih, Marwan
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Inc. 2019
Onderwerpen:
Gastrointestinal Cancer
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066697/
https://ncbi.nlm.nih.gov/pubmed/32162812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0441
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items